Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study

Table 1 Patient background characteristics

Background characteristics		Mean	Median
Age		59.2	61.0
Disease duration (months)		80.2	36.0
Number of swollen joints		8.2	7.0
Number of tender joints		9.4	8.0
DAS28ESR		5.7	5.7
DAS28CRP		5.0	4.9
ESR (mm/h)		51.4	47.5
CRP (mg/dL)		2.6	1.2
RF (IU/mL)		164.9	64.4
MMP-3 (ng/mL)		272.5	152.0
Dose of MTX (mg/week)		9.7	10.0
Dose of GC (mg/day in prednisolone equivalent)		1.3	0.0
Failure in csDMARDs		2.0	2.0
		Frequency	Percent
Gender	Female	1307	81.0
Gender	Male	307	19.0
Entry phase	I	115	7.1
	II	442	27.4
	III	1056	65.5
Biologics	IFX	643	39.8
	ETA	372	23.1
	ADA	404	25.0
	GLM	25	1.6
	CZP	170	10.5
Use of corticosteroid		446	27.6
Use of MTX		1436	89.0
Failure in > 2 csDMARDs		903	56.0
RF positive*		1215	75.6

*RF > 20 IU/mL was defined as positive
CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28 disease activity score for 28 joints, RF rheumatoid factor, MMP-3 matrix metalloproteinase, MTX methotrexate, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs

ISSN: 1478-6362